Canagliflozin vs Dapagliflozin

Both canagliflozin and dapagliflozin effectively lower HbA1c by approximately 0.7% to 1.0% when used as add-on therapy to metformin, according to clinical trials. Head-to-head data is limited, but network meta-analyses suggest similar glycemic efficacy at standard doses.

Beyond blood sugar, both drugs have demonstrated cardiovascular benefits. The CANVAS trial showed canagliflozin reduced major cardiovascular events, while the DECLARE-TIMI 58 trial showed dapagliflozin reduced heart failure hospitalizations. Dapagliflozin also has an FDA-approved indication for heart failure (with or without diabetes) and chronic kidney disease, giving it a broader label.

Both medications share common SGLT2 inhibitor side effects including genital yeast infections, urinary tract infections, and increased urination. These are generally mild and related to the mechanism of action.

A key safety difference involves canagliflozin: the CANVAS trial identified an increased risk of lower-limb amputations compared to placebo. The FDA initially added a boxed warning, though it was later removed in 2020 after additional data. This risk has not been associated with dapagliflozin. Both drugs carry warnings for diabetic ketoacidosis, though this is rare.

Both medications can cause dehydration and low blood pressure, especially in older adults or those taking diuretics.

Both canagliflozin and dapagliflozin are branded medications that can be expensive without insurance, typically ranging from 500 to 600 dollars per month at retail price. Generic versions of both are now becoming available, which significantly reduces costs.

Insurance coverage varies by plan. Many insurers have a preferred SGLT2 inhibitor on their formulary.

Both drugs are taken once daily by mouth, making them equally convenient. Canagliflozin is available in 100 mg and 300 mg tablets, while dapagliflozin comes in 5 mg and 10 mg tablets. Neither requires dose titration based on blood sugar monitoring.

Dapagliflozin has a broader set of approved indications (type 2 diabetes, heart failure, chronic kidney disease), which may simplify prescribing for patients with multiple conditions.

Choosing between canagliflozin and dapagliflozin depends on your specific health situation. If you have heart failure or chronic kidney disease in addition to diabetes, dapagliflozin may be preferred because of its broader FDA-approved indications.

If you have a history of peripheral vascular disease or are at risk for lower-limb complications, your doctor may prefer dapagliflozin. However, this risk is considered low overall.

Ultimately, both are effective SGLT2 inhibitors with proven cardiovascular and kidney benefits. Your doctor may also consider which drug is better covered by your insurance plan.